Accelerated recovery and disposition from rocuronium in an end-stage renal failure patient on chronic anticonvulsant therapy with sodium valproate and primidone.
An end-stage renal failure patient, receiving chronic treatment with the anticonvulsants, sodium valproate and primidone, showed accelerated recovery with enhanced elimination (T1/2(z) = 52 min) and clearance (Cl = 14.4 ml min-1 kg-1) of rocuronium. The pharmacokinetic and pharmacodynamic effects of rocuronium in this patient are compared with those published for healthy and renal failure patients. Increased hepatic binding of rocuronium rather than metabolism is suggested as the possible cause of this effect.
Driessen
J J
JJ
Department of Anaesthesiology, Academic Hospital Nijmegen Sint Radboud, The Netherlands.
Robertson
E N
EN
Booij
L H
LH
Vree
T B
TB
D000328:Adult; D000732:Androstanols / Q000097:blood / Q000493:pharmacokinetics*; D000927:Anticonvulsants / Q000494:pharmacology*; D004347:Drug Interactions; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood*; D008297:Male; D009469:Neuromuscular Junction / Q000187:drug effects; D003473:Neuromuscular Nondepolarizing Agents / Q000097:blood / Q000493:pharmacokinetics*; D011324:Primidone / Q000494:pharmacology; D000077123:Rocuronium; D014635:Valproic Acid / Q000494:pharmacology
D000732:Androstanols; D000927:Anticonvulsants; D003473:Neuromuscular Nondepolarizing Agents; D011324:Primidone; D014635:Valproic Acid; D000077123:Rocuronium